A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks
about
Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-makingA cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool to optimize stroke prevention in general practice: a study protocol.Contemporary approaches to managing atrial fibrillation: A survey of Australian general practitioners.Old age, high risk medication, polypharmacy: a 'trilogy' of risks in older patients with atrial fibrillation.Optimizing Stroke Prevention in Patients With Atrial Fibrillation: A Cluster-Randomized Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool in Australian General Practice, 2012-2013.Educating patients about warfarin therapy using information technology: A survey on healthcare professionals' perspectivesEfficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study.Drug-drug interactions and their predictors: Results from Indian elderly inpatients.Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk.Decade-long temporal trends in the utilization of preventive medicines by centenarians.Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.The Utilization of Antithrombotic Therapy in Older Australians With Atrial Fibrillation.Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage.Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria.
P2860
Q33949571-A97DDC9B-45D5-499A-989C-4258BB05A76EQ35089113-9F7C2A2A-1969-4FEA-8A93-673E65B19B61Q36360590-D7436C11-4257-4F31-8152-547665A343F9Q37060185-FE6A3B6A-62DF-4397-8966-EBB8AE4B99C1Q37109120-7EAD8246-B763-4C3A-BEA0-1665A5C8A282Q37190871-33B4BED8-D28E-4442-9B57-BB52F210A7D8Q37362054-2BA03D26-705A-4AEC-87CE-3232CC747D29Q37407206-DD794D3E-988A-460B-8049-FD13EA8F05D5Q38803355-92072C03-4F6E-47AE-BBC2-E0866EA81C15Q39108862-4B480CA9-51CB-4E65-A7C1-78D7C2ADA4B4Q39659827-93B22ACE-8CFA-4B7E-BB52-0ADF2A8BBDA6Q39905570-B33E99F0-2054-4539-B7CB-1283168CD6BBQ49378467-0222DEE5-987A-4CEB-8590-A807F6D22A3FQ53686521-F362DA02-995F-4529-9949-20441191E05C
P2860
A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A review of the safety of anti ...... the benefits against the risks
@ast
A review of the safety of anti ...... the benefits against the risks
@en
type
label
A review of the safety of anti ...... the benefits against the risks
@ast
A review of the safety of anti ...... the benefits against the risks
@en
prefLabel
A review of the safety of anti ...... the benefits against the risks
@ast
A review of the safety of anti ...... the benefits against the risks
@en
P2860
P356
P1476
A review of the safety of anti ...... the benefits against the risks
@en
P2093
Beata Bajorek
P2860
P356
10.1177/2042098611400495
P577
2011-04-01T00:00:00Z